Additional biomarker studies performed during these clinical trials may reveal whether the PIK3CA mutation can be used as a biomarker to predict the efficacy of PI3K inhibitors in patients with ESCC. This evidence concerns the gene PIK3CA and esophageal squamous cell carcinoma.